SIRT1 and colorectal carcinoma: In addition, other studies have also reported that SIRT1 can participate in tumor immune escape (Meng et al., 2021), drug resistance (Zhao B. et al., 2022), and inhibition of CRC through miRNA (Sun et al., 2017).